PURPOSE: In vitro in the R1M cell model and in vivo in the R1M tumour-bearing athymic model, both [(123)I]-2-iodo-L: -phenylalanine and [(123)I]-2-iodo-D: -phenylalanine have shown promising results as tumour diagnostic agents for SPECT. In order to compare these two amino acid analogues and to examine whether the observed characteristics could be generalised, both isomers were evaluated in various tumour models. METHODS: Transport type characterisation in vitro in A549, A2058, C6, C32, Capan2, EF43fgf4, HT29 and R1M cells with [(123)I]-2-iodo-L: -phenylalanine was performed using the method described by Shotwell et al. Subsequently, [(123)I]-2-iodo-L: -phenylalanine and [(123)I]-2-iodo-D: -phenylalanine tumour uptake and biodistribution were evaluated using dynamic planar imaging and/or dissection in A549, A2058, C6, C32, Capan2, EF43fgf4, HT29 and R1M inoculated athymic mice. Two-compartment blood modelling of the imaging results was performed. RESULTS: In vitro testing demonstrated that [(123)I]-2-iodo-L: -phenylalanine was transported in all tumour cell lines by LAT1. In all tumour models, the two amino acid analogues showed the same general biodistribution characteristics: high and specific tumour uptake and renal tracer clearance. Two-compartment modelling revealed that the D: -isomer showed a faster blood clearance together with a faster distribution to the peripheral compartment in comparison with [(123)I]-2-iodo-L: -phenylalanine. CONCLUSION: [(123)I]-2-iodo-L: -phenylalanine and its D: -isomer are promising tumour diagnostic agents for dynamic planar imaging. They showed a high and similar uptake in all tested tumours. [(123)I]-2-iodo-D: -phenylalanine showed better tracer characteristics concerning radiation dose to other organs.
PURPOSE: In vitro in the R1M cell model and in vivo in the R1M tumour-bearing athymic model, both [(123)I]-2-iodo-L: -phenylalanine and [(123)I]-2-iodo-D: -phenylalanine have shown promising results as tumour diagnostic agents for SPECT. In order to compare these two amino acid analogues and to examine whether the observed characteristics could be generalised, both isomers were evaluated in various tumour models. METHODS: Transport type characterisation in vitro in A549, A2058, C6, C32, Capan2, EF43fgf4, HT29 and R1M cells with [(123)I]-2-iodo-L: -phenylalanine was performed using the method described by Shotwell et al. Subsequently, [(123)I]-2-iodo-L: -phenylalanine and [(123)I]-2-iodo-D: -phenylalaninetumour uptake and biodistribution were evaluated using dynamic planar imaging and/or dissection in A549, A2058, C6, C32, Capan2, EF43fgf4, HT29 and R1M inoculated athymic mice. Two-compartment blood modelling of the imaging results was performed. RESULTS: In vitro testing demonstrated that [(123)I]-2-iodo-L: -phenylalanine was transported in all tumour cell lines by LAT1. In all tumour models, the two amino acid analogues showed the same general biodistribution characteristics: high and specific tumour uptake and renal tracer clearance. Two-compartment modelling revealed that the D: -isomer showed a faster blood clearance together with a faster distribution to the peripheral compartment in comparison with [(123)I]-2-iodo-L: -phenylalanine. CONCLUSION:[(123)I]-2-iodo-L: -phenylalanine and its D: -isomer are promising tumour diagnostic agents for dynamic planar imaging. They showed a high and similar uptake in all tested tumours. [(123)I]-2-iodo-D: -phenylalanine showed better tracer characteristics concerning radiation dose to other organs.
Authors: O Yanagida; Y Kanai; A Chairoungdua; D K Kim; H Segawa; T Nii; S H Cha; H Matsuo; J Fukushima; Y Fukasawa; Y Tani; Y Taketani; H Uchino; J Y Kim; J Inatomi; I Okayasu; K Miyamoto; E Takeda; T Goya; H Endou Journal: Biochim Biophys Acta Date: 2001-10-01
Authors: B Cornelissen; V Kersemans; L Jans; L Staelens; R Oltenfreiter; T Thonissen; E Achten; G Slegers Journal: Br J Radiol Date: 2005-04 Impact factor: 3.039
Authors: S Samnick; D Hellwig; J B Bader; B F Romeike; J R Moringlane; W Feiden; C-M Kirsch Journal: Nucl Med Commun Date: 2002-02 Impact factor: 1.690
Authors: Tony Lahoutte; John Mertens; Vicky Caveliers; Philippe R Franken; Hendrik Everaert; Axel Bossuyt Journal: J Nucl Med Date: 2003-09 Impact factor: 10.057
Authors: Marleen Keyaerts; Tony Lahoutte; Bart Neyns; Vicky Caveliers; Chris Vanhove; Hendrik Everaert; Ken Kersemans; Philippe R Franken; John Mertens; Axel Bossuyt Journal: Eur J Nucl Med Mol Imaging Date: 2007-01-20 Impact factor: 9.236
Authors: Matthias Bauwens; Marijke De Saint-Hubert; Jan Cleynhens; Laura Brams; Ellen Devos; Felix M Mottaghy; Alfons Verbruggen Journal: PLoS One Date: 2012-06-13 Impact factor: 3.240
Authors: Jeroen Verhoeven; Fabian Hulpia; Ken Kersemans; Julie Bolcaen; Stef De Lombaerde; Jan Goeman; Benedicte Descamps; Giorgio Hallaert; Caroline Van den Broecke; Karel Deblaere; Christian Vanhove; Johan Van der Eycken; Serge Van Calenbergh; Ingeborg Goethals; Filip De Vos Journal: Sci Rep Date: 2019-02-27 Impact factor: 4.379